查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
2015065

多發性骨髓瘤治療市場：2026-2032年全球市場預測（依藥物類別、治療階段、治療方案、治療方法、病患年齡、性別及通路分類）

Multiple Myeloma Drug Market by Drug Class, Line Of Therapy, Treatment Regimen, Route Of Administration, Patient Age, Gender, Distribution Channel - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 192 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，多發性骨髓瘤治療市場價值將達到 24.4 億美元，到 2026 年將成長至 25.9 億美元，到 2032 年將達到 36.9 億美元，複合年成長率為 6.05%。

主要市場統計數據
基準年 2025 24.4億美元
預計年份：2026年 25.9億美元
預測年份 2032 36.9億美元
複合年成長率 (%) 6.05%

全面概述了多發性骨髓瘤的治療分類、臨床決策點和醫療保健服務變量，這些因素影響多發性骨髓瘤的治療。

多發性骨髓瘤曾被認為是一種晚期骨髓惡性腫瘤，如今已發展成為一種複雜的疾病領域，其特徵是治療方法快速進步，患者護理路徑錯綜複雜，需要長期管理。目前的治療模式涉及定向小分子藥物、免疫調節劑、生物製藥和精準醫療平台之間的相互關聯，每一種都改變了臨床實踐模式以及與保險公司的互動方式。在此背景下，相關人員需要一份簡明扼要、基於實證醫學的概述，以闡明治療類別、臨床給藥途徑以及影響藥物應用的商業性因素。

對治療、交付和監管方面的變革進行詳細分析，這些變革從根本上改變了多發性骨髓瘤的治療方法和商業化動態。

多發性骨髓瘤的治療模式正在經歷一場變革性的轉變，其驅動力包括作用機制的多樣化、聯合治療的最佳化以及以患者為中心的給藥模式。近年來，該領域已逐漸從單藥治療轉向合理設計的聯合治療，以利用互補的作用機制。蛋白酶體抑制劑和免疫調節劑通常與單株抗體合併使用，以增強療效的深度和持續時間。同時，生物製劑和免疫效應技術的成熟促使人們重新評估研發重點，申辦方致力於探索早期治療適應症和合併治療策略，以重新定義治療標準。

對 2025 年關稅政策轉變將如何重塑多發性骨髓瘤治療的供應鏈、製造決策、價格談判和准入途徑進行策略性評估。

美國在2025年實施的新關稅進一步加劇了全球醫藥供應鏈的複雜性，對採購、生產和成本管理都產生了影響。關稅導致的成本增加影響了原料藥、中間體以及某些進口生物製劑原料的採購，促使製造商重新評估其供應商組合，並在可能的情況下將生產遷回本國或進行區域化生產以降低風險。這些策略調整對短期產業計畫和長期生產能力資本投資都產生了影響。

實證細分洞察揭示了藥物類別、治療方案、給藥途徑、人口統計和分銷如何相互交織並影響臨床和商業性選擇。

基於細分市場的洞察揭示了臨床、人口統計和分佈變量如何相互交織並影響治療方法選擇和商業性優先事項。從藥物類別來看，免疫調節劑如來Lenalidomide、Pomalidomide和沙利度胺在許多治療方案中仍然佔據基礎地位，並且經常與蛋白酶體抑製劑如Bortezomib、Carfilzomib和伊沙佐米聯合使用，構建核心治療方案。單株抗體如Daratumumab、Elotuzumab和伊沙妥昔單抗擴大用於聯合治療策略以增強療效，而組蛋白去乙醯化酶抑制劑（例如Panobinostat）在某些難治性病例中發揮作用。

對美洲、歐洲、中東和非洲以及亞太地區的治療模式、監管流程、報銷環境和人口趨勢的差異進行區域分析。

區域趨勢持續對多發性骨髓瘤的治療策略產生決定性影響，美洲、歐洲、中東和非洲（EMEA）以及亞太地區在臨床實踐、報銷框架和患者群體特徵方面均存在顯著差異。在美洲，新型藥物和聯合治療的快速應用是臨床實踐中的一個顯著趨勢，這得益於先進的臨床試驗網路以及日益重視明確價值差異和真實世界臨床結果的支付方環境。該地區關於藥物可及性的討論通常集中在證明延長總生存期、改善無惡化生存期以及具有衛生經濟價值提案。

對競爭定位進行簡明策略評估，其中現有產品線、新產品進入者和合作策略決定了臨床差異化和商業性優勢。

多發性骨髓瘤領域的競爭格局既包括成熟的腫瘤治療領導企業，也包括敏捷的生物技術公司，這些公司透過創新的作用機制、聯合治療策略和循證醫學項目，推動治療差異化。以蛋白酶體抑制劑和免疫調節劑為核心的現有產品組合在臨床路徑中繼續發揮關鍵作用，而單株抗體產品則在拓展適應症，並改善服務模式，以支持門診和皮下給藥。

商業和臨床領導者採取切實可行的合作策略措施，以確保多發性骨髓瘤的治療機會，最佳化治療方法，並增強供應韌性。

致力於鞏固其在多發性骨髓瘤領域地位的行業領導者應採取協調一致且切實可行的措施，以解決臨床差異化、可及性和營運韌性等問題。首先，應優先進行對比研究和真實世界研究，以證明其療法在相關治療方案中具有超越現有標準的臨床效益。這包括直接對比試驗和反映常規給藥途徑和患者族群特徵的可操作性觀察性研究。其次，應制定最佳化治療方案相容性的產品組合策略，確保其療法在雙聯、三聯或四聯聯合治療框架中具有顯著優勢，同時兼顧耐受性和支持性治療需求。

為了確保獲得可靠的見解，我們採用透明、多方面的研究途徑，結合與專家的直接訪談、系統性的文獻整合和交叉檢驗的分析方法。

本報告的調查方法嚴謹地整合了已發表的科學文獻、監管申報文件、臨床試驗註冊數據以及與臨床醫生、保險公司和行業領袖的訪談。主要研究內容包括對來自不同臨床環境的關鍵意見領袖 (KOL) 和執業醫師進行結構化訪談，以檢驗臨床引入模式，並了解真實世界中的耐受性和給藥偏好。次要研究則系統性地回顧了同儕審查的研究、監管申報文件和指南說明，以闡明治療機制、適應症和安全性。

總結了整合臨床創新、實際情況和政策趨勢的結論，以指導多發性骨髓瘤的策略決策。

這份執行概要強調，多發性骨髓瘤是一個快速發展的治療領域，臨床創新、治療模式轉型和政策變化相互交織，重新定義了患者照護和商業策略。先進生物製藥、最佳化聯合治療和患者偏好的給藥途徑的融合，要求在證據生成、供應鏈設計和市場進入規劃方面採取綜合方法。能夠平衡臨床差異化和可操作運作能力的相關人員，將更有能力將科學進步轉化為對患者的持久影響。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章 多發性骨髓瘤治療市場：依藥物類別分類

  • 組蛋白去乙醯化酶抑制劑
  • 免疫調節劑
    • Lenalidomide
    • Pomalidomide
    • Thalidomide
  • 單株抗體
    • Daratumumab
    • Elotuzumab
    • 伊薩茨基馬
  • 蛋白酶體抑制劑
    • Bortezomib
    • Carfilzomib
    • 伊沙佐米

第9章 多發性骨髓瘤治療市場：依治療階段分類

  • 第 1 行
  • 第二行
  • 從第三行開始

第10章 多發性骨髓瘤治療市場：依治療方法

  • 聯合治療
    • 雙重聯合治療
    • 二次聯合治療
    • 三聯聯合治療
  • 單藥治療

第11章 多發性骨髓瘤治療藥物市場：依給藥途徑分類

  • 靜脈
  • 口服
  • 皮下

第12章 多發性骨髓瘤治療市場：依病患年齡分類

  • 60歲或以上
  • 60歲以下

第13章 多發性骨髓瘤治療藥物市場：依性別分類

  • 女士
  • 男性

第14章 多發性骨髓瘤治療藥物市場：依通路分類

  • 醫院藥房
  • 網路藥房
  • 零售藥房

第15章 多發性骨髓瘤治療藥物市場：按地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第16章 多發性骨髓瘤治療藥物市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第17章 多發性骨髓瘤治療藥物市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第18章：美國多發性骨髓瘤療法市場

第19章：中國多發性骨髓瘤治療藥物市場

第20章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • AbbVie Inc.
  • Amgen Inc.
  • AstraZeneca Plc
  • Bristol-Myers Squibb Company
  • GlaxoSmithKline plc
  • Janssen Biotech, Inc.
  • Karyopharm Therapeutics Inc.
  • Novartis International AG
  • Sanofi SA
  • Takeda Pharmaceutical Company Limited
  • Teva Pharmaceutical Industries Ltd.
Product Code: MRR-036C5CF3A894

The Multiple Myeloma Drug Market was valued at USD 2.44 billion in 2025 and is projected to grow to USD 2.59 billion in 2026, with a CAGR of 6.05%, reaching USD 3.69 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 2.44 billion
Estimated Year [2026] USD 2.59 billion
Forecast Year [2032] USD 3.69 billion
CAGR (%) 6.05%

A comprehensive orienting overview that defines therapeutic classes, clinical decision nodes, and care delivery variables shaping multiple myeloma management

Multiple myeloma has evolved from a terminal hematologic malignancy to a complex, chronically managed disease area characterized by rapid therapeutic innovation and nuanced patient pathways. The landscape now interweaves targeted small molecules, immune-modulating compounds, biologics, and precision-directed platforms, each altering clinical practice patterns and payer conversations. Against this backdrop, stakeholders require a succinct, evidence-driven introduction that clarifies therapeutic categories, real-world administration pathways, and the commercial levers shaping adoption.

This executive introduction sets the stage by articulating the current therapeutic taxonomy and common clinical decision nodes. Drug classes of central relevance include histone deacetylase inhibitors exemplified by panobinostat, immunomodulatory agents such as lenalidomide, pomalidomide, and thalidomide, monoclonal antibodies including daratumumab, elotuzumab, and isatuximab, and proteasome inhibitors represented by bortezomib, carfilzomib, and ixazomib. Alongside these classes, treatment selection is influenced by line of therapy considerations spanning first line through third and beyond, and by regimen architecture that ranges from monotherapy to combination approaches including doublet, triplet, and quadruplet regimens.

Finally, the introduction underscores practical variables that shape real-world utilization: routes of administration including intravenous, oral, and subcutaneous delivery; patient demographic factors such as age cohorts sixty and above versus under sixty; gender-specific care pathways; and distribution channel distinctions across hospital, online, and retail pharmacy settings. By clarifying these foundational elements, this section equips executives and clinicians to interpret subsequent sections with precision and context.

An in-depth exploration of the therapeutic, delivery, and regulatory shifts fundamentally altering multiple myeloma treatment approaches and commercialization dynamics

Multiple myeloma treatment paradigms are undergoing transformative shifts driven by mechanistic diversification, combination optimization, and patient-centric delivery models. Over recent years, the field has moved beyond sequential monotherapy toward rationally designed combinations that leverage complementary mechanisms of action; proteasome inhibitors and immunomodulatory agents are commonly paired with monoclonal antibodies to enhance depth and durability of response. Concurrently, the maturation of biologics and immune effector technologies has reoriented R&D priorities, prompting sponsors to pursue earlier-line indications and combination strategies that redefine standard-of-care benchmarks.

Technological changes are also reshaping care delivery. Oral formulations and subcutaneous biologic options reduce clinic time and support outpatient management, which in turn influences payer negotiations and patient adherence dynamics. Treatment regimen innovation now frequently emphasizes triplet and quadruplet approaches in frontline settings where tolerability permits, while second-line and later settings prioritize sequencing and combination flexibility to manage resistance. These shifts are accompanied by evolving regulatory pathways and real-world evidence expectations, requiring developers to demonstrate not only efficacy but also comparative benefits in quality of life, progression control, and resource utilization.

As a result, commercial models are adapting: manufacturers and providers must align product positioning with differentiated clinical profiles across lines of therapy, tailor messaging for distinct patient age cohorts and genders, and design distribution strategies that incorporate hospital pharmacies, retail outlets, and increasingly important online channels. The net effect is a faster-moving, more fragmented landscape where strategic agility and multidisciplinary evidence generation confer competitive advantage.

A strategic assessment of how tariff policy shifts in 2025 are reshaping supply chains, manufacturing decisions, pricing negotiations, and access pathways in multiple myeloma care

The implementation of new United States tariff measures in 2025 has introduced an additional layer of complexity to global pharmaceutical supply chains, with implications for sourcing, manufacturing, and cost management. Tariff-driven cost inflation affects active pharmaceutical ingredient procurement, intermediate components, and certain imported biologic materials, prompting manufacturers to reassess supplier portfolios and, where feasible, repatriate or regionalize production to mitigate exposure. These strategic adjustments shape both short-term operational planning and longer-term capital investments in manufacturing capacity.

In parallel, tariff-induced changes influence pricing and contracting discussions with payers and integrated delivery networks. Pharmaceutical companies face pressure to absorb incremental costs, negotiate updated reimbursement terms, or implement targeted patient assistance strategies to preserve access. For therapies that rely on complex cold-chain logistics and specialized distribution-such as monoclonal antibodies administered intravenously or subcutaneously-the combination of tariffs and logistics cost increases intensifies the need for integrated supply chain resilience.

Moreover, tariffs catalyze a reevaluation of commercial strategy across therapeutic classes and route-of-administration preferences. Oral agents that reduce clinic burden can offer resilience against distribution cost volatility, while hospital-centric intravenous therapies may face more pronounced operational cost scrutiny. For decision-makers, the cumulative impact of tariff policy requires a cross-functional response that spans procurement, regulatory planning, market access, and value communication to sustain patient access and preserve therapeutic continuity.

Empirical segmentation insights revealing how drug class, therapy line, regimen architecture, administration route, demographics, and distribution converge to shape clinical and commercial choices

Segmentation-driven insight reveals how clinical, demographic, and distribution variables intersect to influence therapeutic selection and commercial priorities. When analyzing drug classes, immunomodulatory agents such as lenalidomide, pomalidomide, and thalidomide remain foundational across many lines of therapy and are frequently paired with proteasome inhibitors like bortezomib, carfilzomib, and ixazomib to create backbone regimens. Monoclonal antibodies, including daratumumab, elotuzumab, and isatuximab, are increasingly used in combination strategies to deepen responses, while histone deacetylase inhibitors exemplified by panobinostat occupy a role in selected refractory settings.

Line of therapy segmentation-spanning first line through third and beyond-drives regimen architecture, with frontline treatments prioritizing tolerability and long-term disease control, and later lines emphasizing salvage efficacy and sequencing flexibility. Treatment regimen distinctions between monotherapy and combination therapy are critical: combination approaches, whether doublet, triplet, or quadruplet, are driving improved response rates but also elevate considerations around toxicity management, supportive care, and reimbursement. Route of administration segmentation underscores patient-centric trade-offs; intravenous and subcutaneous biologics demand clinic resources, whereas oral agents support outpatient management and potentially higher adherence.

Patient age cohorts-sixty and above versus under sixty-and gender differences further refine therapeutic decisions, influencing tolerability assessments, comorbidity management, and transplant eligibility considerations. Finally, distribution channel segmentation across hospital, online, and retail pharmacies shapes access and patient experience, with each channel imposing distinct logistical, reimbursement, and patient support requirements. Integrating these segmentation lenses enables tailored clinical development and commercial strategies that align product attributes with real-world care pathways.

A regionally focused analysis of how treatment patterns, regulatory processes, reimbursement environments, and demographic trends vary across the Americas, EMEA, and Asia-Pacific

Regional dynamics continue to exert a decisive influence on multiple myeloma strategy, with the Americas, Europe Middle East & Africa, and Asia-Pacific each presenting distinct clinical practices, reimbursement frameworks, and patient demographics. In the Americas, practice patterns emphasize rapid adoption of novel agents and combination regimens, buoyed by advanced clinical trial networks and a payer environment that increasingly rewards clear value differentiation and real-world outcomes. Access conversations in this region are often centered on demonstrating overall survival benefit, progression-free survival improvements, and health economic value propositions.

In Europe, the Middle East, and Africa, heterogeneity in healthcare funding models and regulatory requirements necessitates region-specific evidence plans and pricing strategies. Centralized regulatory pathways coexist with country-level reimbursement decisions, making local health technology assessment dossiers and real-world evidence generation essential to secure access. In many countries across this region, treatment delivery models emphasize hospital-based administration, which influences preferences for subcutaneous formulations and protocols that streamline infusion center throughput.

Asia-Pacific markets demonstrate accelerating clinical research activity and rising demand for oral and outpatient-friendly therapeutics driven by demographic trends and healthcare modernization initiatives. Supply chain considerations and tariff policies also play a heightened role in some Asia-Pacific jurisdictions, prompting manufacturers to consider regional manufacturing partnerships and tailored distribution models. Across all regions, demographic variations such as age distribution and gender-related epidemiology further inform product positioning and market access pathways.

A concise strategic review of competitive positioning where incumbent franchises, novel entrants, and partnership strategies define clinical differentiation and commercial advantage

Competitive dynamics in multiple myeloma are defined by both established oncology leaders and agile specialty biotechs that drive therapeutic differentiation through novel mechanisms, combination strategies, and evidence-generation programs. Incumbent product portfolios anchored by proteasome inhibitors and immunomodulatory agents continue to play a central role in clinical pathways, while monoclonal antibody franchises have expanded indications and service models to support clinic-based and subcutaneous administration.

Emerging entrants are accelerating innovation through bispecific antibodies, cellular therapies, and next-generation targeted agents, compelling larger organizations to invest in combination trials and lifecycle management tactics. Strategic activity includes label expansion through earlier-line studies, formulation improvements that enhance outpatient delivery, and the development of companion diagnostics or biomarker strategies that refine patient selection. Partnerships and licensing arrangements are prevalent as companies seek complementary assets to build robust regimen offerings and to broaden geographic reach.

From a commercial perspective, companies are differentiating through patient support solutions, digital adherence programs, and integrated value dossiers that align clinical outcomes with cost and quality-of-life metrics. The interplay between clinical evidence, manufacturing scale, and payer engagement determines competitive positioning, and successful players will be those that align scientific differentiation with operational excellence and demonstrable value to health systems and patients.

Actionable and coordinated strategic moves for commercial and clinical leaders to secure access, optimize regimens, and strengthen supply resilience in multiple myeloma

Industry leaders seeking to strengthen their foothold in multiple myeloma should pursue a set of coordinated, actionable interventions that address clinical differentiation, access, and operational resilience. First, prioritize the generation of comparative and real-world evidence that demonstrates clinical benefit beyond existing standards of care across relevant lines of therapy; this includes head-to-head studies and pragmatic observational research that reflect routine administration routes and patient demographics. Second, design portfolio strategies that optimize regimen compatibility, enabling your assets to be convincingly positioned in doublet, triplet, or quadruplet frameworks while managing tolerability and supportive care needs.

Simultaneously, invest in distribution and patient support models that reflect shifting care settings: enhance capabilities for outpatient and home-based administration where feasible, and tailor engagement for hospital pharmacy stakeholders and online retail channels. Supply chain diversification and regional manufacturing contingency planning will mitigate exposure to tariff volatility and logistics disruption. From a commercial standpoint, refine value communication to payers by linking clinical endpoints to economic outcomes, and develop targeted patient assistance programs that maintain adherence across oral and injectable modalities.

Finally, embed cross-functional collaboration among R&D, market access, and commercial teams to accelerate label expansion strategies and to ensure evidence generation aligns with reimbursement requirements. By executing these linked actions, industry leaders can enhance access, sustain uptake, and preserve long-term therapeutic relevance in a rapidly evolving multiple myeloma landscape.

A transparent and multi-method research approach combining primary expert interviews, systematic literature synthesis, and cross-validated analytical techniques to ensure robust insights

The research methodology for this report combines a rigorous synthesis of public scientific literature, regulatory filings, clinical trial registries, and stakeholder interviews with clinicians, payers, and commercial leaders. Primary research components include structured interviews with key opinion leaders and treating physicians across multiple practice settings to validate clinical adoption patterns and to capture real-world tolerability and administration preferences. Secondary research involves systematic review of peer-reviewed studies, regulatory documentation, and guideline statements to map therapeutic mechanisms, label indications, and safety profiles.

Data triangulation was employed to reconcile insights from disparate sources, using cross-validation techniques to ensure consistency between clinical trial outcomes and observed real-world usage. Coverage of segmentation lenses-drug class including histone deacetylase inhibitors, immunomodulatory agents, monoclonal antibodies, and proteasome inhibitors; line of therapy distinctions; regimen architecture; route of administration; patient age and gender cohorts; and distribution channels-was achieved through targeted dataset extraction and expert validation. Regional analyses were informed by jurisdictional regulatory materials and interviews with local market experts in the Americas, Europe Middle East & Africa, and Asia-Pacific.

Analytical methods included qualitative thematic coding of interview data, comparative benefit-risk assessments across therapeutic classes, and scenario-based impact modeling to evaluate strategic implications such as tariff effects and supply chain adaptations. Throughout, transparency in source attribution and methodological limitations was maintained to support reproducibility and to guide appropriate interpretation of findings.

A concluding synthesis that integrates clinical innovation, operational realities, and policy dynamics to guide strategic decision-making in multiple myeloma

This executive synthesis underscores that multiple myeloma is a rapidly evolving therapeutic arena where clinical innovation, delivery model transformation, and policy shifts intersect to redefine patient care and commercial strategy. The convergence of advanced biologics, optimized combination regimens, and patient-preferred administration routes necessitates a holistic approach to evidence generation, supply chain design, and market access planning. Stakeholders who align clinical differentiation with pragmatic operational capabilities will be best positioned to translate scientific advances into sustained patient impact.

Moreover, external forces such as tariff changes and regional regulatory heterogeneity require proactive, cross-functional responses to preserve access and affordability. Integrating segmentation insights-from drug class and line of therapy through regimen composition, administration route, age and gender demographics, and distribution channels-enables more precise product positioning and tailored launch strategies. Ultimately, the capacity to demonstrate meaningful clinical benefit, manage logistical complexity, and communicate value to payers and providers will determine which therapies achieve durable uptake and which face access constraints.

Decision-makers should therefore take a coordinated approach that balances aggressive evidence generation with pragmatic commercialization planning, ensuring that therapeutic innovation translates into measurable improvements in patient outcomes and health system value.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Multiple Myeloma Drug Market, by Drug Class

  • 8.1. Histone Deacetylase Inhibitors
  • 8.2. Immunomodulatory Agents
    • 8.2.1. Lenalidomide
    • 8.2.2. Pomalidomide
    • 8.2.3. Thalidomide
  • 8.3. Monoclonal Antibodies
    • 8.3.1. Daratumumab
    • 8.3.2. Elotuzumab
    • 8.3.3. Isatuximab
  • 8.4. Proteasome Inhibitors
    • 8.4.1. Bortezomib
    • 8.4.2. Carfilzomib
    • 8.4.3. Ixazomib

9. Multiple Myeloma Drug Market, by Line Of Therapy

  • 9.1. First Line
  • 9.2. Second Line
  • 9.3. Third And Beyond

10. Multiple Myeloma Drug Market, by Treatment Regimen

  • 10.1. Combination Therapy
    • 10.1.1. Doublet Regimen
    • 10.1.2. Quadruplet Regimen
    • 10.1.3. Triplet Regimen
  • 10.2. Monotherapy

11. Multiple Myeloma Drug Market, by Route Of Administration

  • 11.1. Intravenous
  • 11.2. Oral
  • 11.3. Subcutaneous

12. Multiple Myeloma Drug Market, by Patient Age

  • 12.1. Sixty And Above
  • 12.2. Under Sixty

13. Multiple Myeloma Drug Market, by Gender

  • 13.1. Female
  • 13.2. Male

14. Multiple Myeloma Drug Market, by Distribution Channel

  • 14.1. Hospital Pharmacy
  • 14.2. Online Pharmacy
  • 14.3. Retail Pharmacy

15. Multiple Myeloma Drug Market, by Region

  • 15.1. Americas
    • 15.1.1. North America
    • 15.1.2. Latin America
  • 15.2. Europe, Middle East & Africa
    • 15.2.1. Europe
    • 15.2.2. Middle East
    • 15.2.3. Africa
  • 15.3. Asia-Pacific

16. Multiple Myeloma Drug Market, by Group

  • 16.1. ASEAN
  • 16.2. GCC
  • 16.3. European Union
  • 16.4. BRICS
  • 16.5. G7
  • 16.6. NATO

17. Multiple Myeloma Drug Market, by Country

  • 17.1. United States
  • 17.2. Canada
  • 17.3. Mexico
  • 17.4. Brazil
  • 17.5. United Kingdom
  • 17.6. Germany
  • 17.7. France
  • 17.8. Russia
  • 17.9. Italy
  • 17.10. Spain
  • 17.11. China
  • 17.12. India
  • 17.13. Japan
  • 17.14. Australia
  • 17.15. South Korea

18. United States Multiple Myeloma Drug Market

19. China Multiple Myeloma Drug Market

20. Competitive Landscape

  • 20.1. Market Concentration Analysis, 2025
    • 20.1.1. Concentration Ratio (CR)
    • 20.1.2. Herfindahl Hirschman Index (HHI)
  • 20.2. Recent Developments & Impact Analysis, 2025
  • 20.3. Product Portfolio Analysis, 2025
  • 20.4. Benchmarking Analysis, 2025
  • 20.5. AbbVie Inc.
  • 20.6. Amgen Inc.
  • 20.7. AstraZeneca Plc
  • 20.8. Bristol-Myers Squibb Company
  • 20.9. GlaxoSmithKline plc
  • 20.10. Janssen Biotech, Inc.
  • 20.11. Karyopharm Therapeutics Inc.
  • 20.12. Novartis International AG
  • 20.13. Sanofi S.A.
  • 20.14. Takeda Pharmaceutical Company Limited
  • 20.15. Teva Pharmaceutical Industries Ltd.

LIST OF FIGURES

  • FIGURE 1. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL MULTIPLE MYELOMA DRUG MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL MULTIPLE MYELOMA DRUG MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY DRUG CLASS, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY LINE OF THERAPY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY TREATMENT REGIMEN, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY PATIENT AGE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY GENDER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 13. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 14. UNITED STATES MULTIPLE MYELOMA DRUG MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 15. CHINA MULTIPLE MYELOMA DRUG MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY HISTONE DEACETYLASE INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY HISTONE DEACETYLASE INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY HISTONE DEACETYLASE INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY IMMUNOMODULATORY AGENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY IMMUNOMODULATORY AGENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY IMMUNOMODULATORY AGENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY IMMUNOMODULATORY AGENTS, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY LENALIDOMIDE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY LENALIDOMIDE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY LENALIDOMIDE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY POMALIDOMIDE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY POMALIDOMIDE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY POMALIDOMIDE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY THALIDOMIDE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY THALIDOMIDE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY THALIDOMIDE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY DARATUMUMAB, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY DARATUMUMAB, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY DARATUMUMAB, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY ELOTUZUMAB, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY ELOTUZUMAB, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY ELOTUZUMAB, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY ISATUXIMAB, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY ISATUXIMAB, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY ISATUXIMAB, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY PROTEASOME INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY PROTEASOME INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY PROTEASOME INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY PROTEASOME INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY BORTEZOMIB, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY BORTEZOMIB, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY BORTEZOMIB, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY CARFILZOMIB, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY CARFILZOMIB, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY CARFILZOMIB, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY IXAZOMIB, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY IXAZOMIB, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY IXAZOMIB, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY FIRST LINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY FIRST LINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY FIRST LINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY SECOND LINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY SECOND LINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY SECOND LINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY THIRD AND BEYOND, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY THIRD AND BEYOND, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY THIRD AND BEYOND, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY TREATMENT REGIMEN, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY COMBINATION THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY COMBINATION THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY COMBINATION THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY COMBINATION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY DOUBLET REGIMEN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY DOUBLET REGIMEN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY DOUBLET REGIMEN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY QUADRUPLET REGIMEN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY QUADRUPLET REGIMEN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY QUADRUPLET REGIMEN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY TRIPLET REGIMEN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY TRIPLET REGIMEN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY TRIPLET REGIMEN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY MONOTHERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY MONOTHERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY MONOTHERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY ORAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY ORAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY SUBCUTANEOUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY SUBCUTANEOUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY PATIENT AGE, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY SIXTY AND ABOVE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY SIXTY AND ABOVE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY SIXTY AND ABOVE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY UNDER SIXTY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY UNDER SIXTY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY UNDER SIXTY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY GENDER, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY FEMALE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY FEMALE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY FEMALE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY MALE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY MALE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY MALE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY ONLINE PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY ONLINE PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 107. AMERICAS MULTIPLE MYELOMA DRUG MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 108. AMERICAS MULTIPLE MYELOMA DRUG MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 109. AMERICAS MULTIPLE MYELOMA DRUG MARKET SIZE, BY IMMUNOMODULATORY AGENTS, 2018-2032 (USD MILLION)
  • TABLE 110. AMERICAS MULTIPLE MYELOMA DRUG MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 111. AMERICAS MULTIPLE MYELOMA DRUG MARKET SIZE, BY PROTEASOME INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 112. AMERICAS MULTIPLE MYELOMA DRUG MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 113. AMERICAS MULTIPLE MYELOMA DRUG MARKET SIZE, BY TREATMENT REGIMEN, 2018-2032 (USD MILLION)
  • TABLE 114. AMERICAS MULTIPLE MYELOMA DRUG MARKET SIZE, BY COMBINATION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 115. AMERICAS MULTIPLE MYELOMA DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 116. AMERICAS MULTIPLE MYELOMA DRUG MARKET SIZE, BY PATIENT AGE, 2018-2032 (USD MILLION)
  • TABLE 117. AMERICAS MULTIPLE MYELOMA DRUG MARKET SIZE, BY GENDER, 2018-2032 (USD MILLION)
  • TABLE 118. AMERICAS MULTIPLE MYELOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 119. NORTH AMERICA MULTIPLE MYELOMA DRUG MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 120. NORTH AMERICA MULTIPLE MYELOMA DRUG MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 121. NORTH AMERICA MULTIPLE MYELOMA DRUG MARKET SIZE, BY IMMUNOMODULATORY AGENTS, 2018-2032 (USD MILLION)
  • TABLE 122. NORTH AMERICA MULTIPLE MYELOMA DRUG MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 123. NORTH AMERICA MULTIPLE MYELOMA DRUG MARKET SIZE, BY PROTEASOME INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 124. NORTH AMERICA MULTIPLE MYELOMA DRUG MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 125. NORTH AMERICA MULTIPLE MYELOMA DRUG MARKET SIZE, BY TREATMENT REGIMEN, 2018-2032 (USD MILLION)
  • TABLE 126. NORTH AMERICA MULTIPLE MYELOMA DRUG MARKET SIZE, BY COMBINATION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 127. NORTH AMERICA MULTIPLE MYELOMA DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 128. NORTH AMERICA MULTIPLE MYELOMA DRUG MARKET SIZE, BY PATIENT AGE, 2018-2032 (USD MILLION)
  • TABLE 129. NORTH AMERICA MULTIPLE MYELOMA DRUG MARKET SIZE, BY GENDER, 2018-2032 (USD MILLION)
  • TABLE 130. NORTH AMERICA MULTIPLE MYELOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 131. LATIN AMERICA MULTIPLE MYELOMA DRUG MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 132. LATIN AMERICA MULTIPLE MYELOMA DRUG MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 133. LATIN AMERICA MULTIPLE MYELOMA DRUG MARKET SIZE, BY IMMUNOMODULATORY AGENTS, 2018-2032 (USD MILLION)
  • TABLE 134. LATIN AMERICA MULTIPLE MYELOMA DRUG MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 135. LATIN AMERICA MULTIPLE MYELOMA DRUG MARKET SIZE, BY PROTEASOME INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 136. LATIN AMERICA MULTIPLE MYELOMA DRUG MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 137. LATIN AMERICA MULTIPLE MYELOMA DRUG MARKET SIZE, BY TREATMENT REGIMEN, 2018-2032 (USD MILLION)
  • TABLE 138. LATIN AMERICA MULTIPLE MYELOMA DRUG MARKET SIZE, BY COMBINATION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 139. LATIN AMERICA MULTIPLE MYELOMA DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 140. LATIN AMERICA MULTIPLE MYELOMA DRUG MARKET SIZE, BY PATIENT AGE, 2018-2032 (USD MILLION)
  • TABLE 141. LATIN AMERICA MULTIPLE MYELOMA DRUG MARKET SIZE, BY GENDER, 2018-2032 (USD MILLION)
  • TABLE 142. LATIN AMERICA MULTIPLE MYELOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 143. EUROPE, MIDDLE EAST & AFRICA MULTIPLE MYELOMA DRUG MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 144. EUROPE, MIDDLE EAST & AFRICA MULTIPLE MYELOMA DRUG MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 145. EUROPE, MIDDLE EAST & AFRICA MULTIPLE MYELOMA DRUG MARKET SIZE, BY IMMUNOMODULATORY AGENTS, 2018-2032 (USD MILLION)
  • TABLE 146. EUROPE, MIDDLE EAST & AFRICA MULTIPLE MYELOMA DRUG MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 147. EUROPE, MIDDLE EAST & AFRICA MULTIPLE MYELOMA DRUG MARKET SIZE, BY PROTEASOME INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 148. EUROPE, MIDDLE EAST & AFRICA MULTIPLE MYELOMA DRUG MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 149. EUROPE, MIDDLE EAST & AFRICA MULTIPLE MYELOMA DRUG MARKET SIZE, BY TREATMENT REGIMEN, 2018-2032 (USD MILLION)
  • TABLE 150. EUROPE, MIDDLE EAST & AFRICA MULTIPLE MYELOMA DRUG MARKET SIZE, BY COMBINATION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 151. EUROPE, MIDDLE EAST & AFRICA MULTIPLE MYELOMA DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 152. EUROPE, MIDDLE EAST & AFRICA MULTIPLE MYELOMA DRUG MARKET SIZE, BY PATIENT AGE, 2018-2032 (USD MILLION)
  • TABLE 153. EUROPE, MIDDLE EAST & AFRICA MULTIPLE MYELOMA DRUG MARKET SIZE, BY GENDER, 2018-2032 (USD MILLION)
  • TABLE 154. EUROPE, MIDDLE EAST & AFRICA MULTIPLE MYELOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 155. EUROPE MULTIPLE MYELOMA DRUG MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 156. EUROPE MULTIPLE MYELOMA DRUG MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 157. EUROPE MULTIPLE MYELOMA DRUG MARKET SIZE, BY IMMUNOMODULATORY AGENTS, 2018-2032 (USD MILLION)
  • TABLE 158. EUROPE MULTIPLE MYELOMA DRUG MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 159. EUROPE MULTIPLE MYELOMA DRUG MARKET SIZE, BY PROTEASOME INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 160. EUROPE MULTIPLE MYELOMA DRUG MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 161. EUROPE MULTIPLE MYELOMA DRUG MARKET SIZE, BY TREATMENT REGIMEN, 2018-2032 (USD MILLION)
  • TABLE 162. EUROPE MULTIPLE MYELOMA DRUG MARKET SIZE, BY COMBINATION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 163. EUROPE MULTIPLE MYELOMA DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 164. EUROPE MULTIPLE MYELOMA DRUG MARKET SIZE, BY PATIENT AGE, 2018-2032 (USD MILLION)
  • TABLE 165. EUROPE MULTIPLE MYELOMA DRUG MARKET SIZE, BY GENDER, 2018-2032 (USD MILLION)
  • TABLE 166. EUROPE MULTIPLE MYELOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 167. MIDDLE EAST MULTIPLE MYELOMA DRUG MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 168. MIDDLE EAST MULTIPLE MYELOMA DRUG MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 169. MIDDLE EAST MULTIPLE MYELOMA DRUG MARKET SIZE, BY IMMUNOMODULATORY AGENTS, 2018-2032 (USD MILLION)
  • TABLE 170. MIDDLE EAST MULTIPLE MYELOMA DRUG MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 171. MIDDLE EAST MULTIPLE MYELOMA DRUG MARKET SIZE, BY PROTEASOME INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 172. MIDDLE EAST MULTIPLE MYELOMA DRUG MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 173. MIDDLE EAST MULTIPLE MYELOMA DRUG MARKET SIZE, BY TREATMENT REGIMEN, 2018-2032 (USD MILLION)
  • TABLE 174. MIDDLE EAST MULTIPLE MYELOMA DRUG MARKET SIZE, BY COMBINATION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 175. MIDDLE EAST MULTIPLE MYELOMA DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 176. MIDDLE EAST MULTIPLE MYELOMA DRUG MARKET SIZE, BY PATIENT AGE, 2018-2032 (USD MILLION)
  • TABLE 177. MIDDLE EAST MULTIPLE MYELOMA DRUG MARKET SIZE, BY GENDER, 2018-2032 (USD MILLION)
  • TABLE 178. MIDDLE EAST MULTIPLE MYELOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 179. AFRICA MULTIPLE MYELOMA DRUG MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 180. AFRICA MULTIPLE MYELOMA DRUG MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 181. AFRICA MULTIPLE MYELOMA DRUG MARKET SIZE, BY IMMUNOMODULATORY AGENTS, 2018-2032 (USD MILLION)
  • TABLE 182. AFRICA MULTIPLE MYELOMA DRUG MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 183. AFRICA MULTIPLE MYELOMA DRUG MARKET SIZE, BY PROTEASOME INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 184. AFRICA MULTIPLE MYELOMA DRUG MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 185. AFRICA MULTIPLE MYELOMA DRUG MARKET SIZE, BY TREATMENT REGIMEN, 2018-2032 (USD MILLION)
  • TABLE 186. AFRICA MULTIPLE MYELOMA DRUG MARKET SIZE, BY COMBINATION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 187. AFRICA MULTIPLE MYELOMA DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 188. AFRICA MULTIPLE MYELOMA DRUG MARKET SIZE, BY PATIENT AGE, 2018-2032 (USD MILLION)
  • TABLE 189. AFRICA MULTIPLE MYELOMA DRUG MARKET SIZE, BY GENDER, 2018-2032 (USD MILLION)
  • TABLE 190. AFRICA MULTIPLE MYELOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 191. ASIA-PACIFIC MULTIPLE MYELOMA DRUG MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 192. ASIA-PACIFIC MULTIPLE MYELOMA DRUG MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 193. ASIA-PACIFIC MULTIPLE MYELOMA DRUG MARKET SIZE, BY IMMUNOMODULATORY AGENTS, 2018-2032 (USD MILLION)
  • TABLE 194. ASIA-PACIFIC MULTIPLE MYELOMA DRUG MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 195. ASIA-PACIFIC MULTIPLE MYELOMA DRUG MARKET SIZE, BY PROTEASOME INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 196. ASIA-PACIFIC MULTIPLE MYELOMA DRUG MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 197. ASIA-PACIFIC MULTIPLE MYELOMA DRUG MARKET SIZE, BY TREATMENT REGIMEN, 2018-2032 (USD MILLION)
  • TABLE 198. ASIA-PACIFIC MULTIPLE MYELOMA DRUG MARKET SIZE, BY COMBINATION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 199. ASIA-PACIFIC MULTIPLE MYELOMA DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 200. ASIA-PACIFIC MULTIPLE MYELOMA DRUG MARKET SIZE, BY PATIENT AGE, 2018-2032 (USD MILLION)
  • TABLE 201. ASIA-PACIFIC MULTIPLE MYELOMA DRUG MARKET SIZE, BY GENDER, 2018-2032 (USD MILLION)
  • TABLE 202. ASIA-PACIFIC MULTIPLE MYELOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 203. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 204. ASEAN MULTIPLE MYELOMA DRUG MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 205. ASEAN MULTIPLE MYELOMA DRUG MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 206. ASEAN MULTIPLE MYELOMA DRUG MARKET SIZE, BY IMMUNOMODULATORY AGENTS, 2018-2032 (USD MILLION)
  • TABLE 207. ASEAN MULTIPLE MYELOMA DRUG MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 208. ASEAN MULTIPLE MYELOMA DRUG MARKET SIZE, BY PROTEASOME INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 209. ASEAN MULTIPLE MYELOMA DRUG MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 210. ASEAN MULTIPLE MYELOMA DRUG MARKET SIZE, BY TREATMENT REGIMEN, 2018-2032 (USD MILLION)
  • TABLE 211. ASEAN MULTIPLE MYELOMA DRUG MARKET SIZE, BY COMBINATION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 212. ASEAN MULTIPLE MYELOMA DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 213. ASEAN MULTIPLE MYELOMA DRUG MARKET SIZE, BY PATIENT AGE, 2018-2032 (USD MILLION)
  • TABLE 214. ASEAN MULTIPLE MYELOMA DRUG MARKET SIZE, BY GENDER, 2018-2032 (USD MILLION)
  • TABLE 215. ASEAN MULTIPLE MYELOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 216. GCC MULTIPLE MYELOMA DRUG MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 217. GCC MULTIPLE MYELOMA DRUG MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 218. GCC MULTIPLE MYELOMA DRUG MARKET SIZE, BY IMMUNOMODULATORY AGENTS, 2018-2032 (USD MILLION)
  • TABLE 219. GCC MULTIPLE MYELOMA DRUG MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 220. GCC MULTIPLE MYELOMA DRUG MARKET SIZE, BY PROTEASOME INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 221. GCC MULTIPLE MYELOMA DRUG MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 222. GCC MULTIPLE MYELOMA DRUG MARKET SIZE, BY TREATMENT REGIMEN, 2018-2032 (USD MILLION)
  • TABLE 223. GCC MULTIPLE MYELOMA DRUG MARKET SIZE, BY COMBINATION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 224. GCC MULTIPLE MYELOMA DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 225. GCC MULTIPLE MYELOMA DRUG MARKET SIZE, BY PATIENT AGE, 2018-2032 (USD MILLION)
  • TABLE 226. GCC MULTIPLE MYELOMA DRUG MARKET SIZE, BY GENDER, 2018-2032 (USD MILLION)
  • TABLE 227. GCC MULTIPLE MYELOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 228. EUROPEAN UNION MULTIPLE MYELOMA DRUG MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 229. EUROPEAN UNION MULTIPLE MYELOMA DRUG MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 230. EUROPEAN UNION MULTIPLE MYELOMA DRUG MARKET SIZE, BY IMMUNOMODULATORY AGENTS, 2018-2032 (USD MILLION)
  • TABLE 231. EUROPEAN UNION MULTIPLE MYELOMA DRUG MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 232. EUROPEAN UNION MULTIPLE MYELOMA DRUG MARKET SIZE, BY PROTEASOME INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 233. EUROPEAN UNION MULTIPLE MYELOMA DRUG MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 234. EUROPEAN UNION MULTIPLE MYELOMA DRUG MARKET SIZE, BY TREATMENT REGIMEN, 2018-2032 (USD MILLION)
  • TABLE 235. EUROPEAN UNION MULTIPLE MYELOMA DRUG MARKET SIZE, BY COMBINATION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 236. EUROPEAN UNION MULTIPLE MYELOMA DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 237. EUROPEAN UNION MULTIPLE MYELOMA DRUG MARKET SIZE, BY PATIENT AGE, 2018-2032 (USD MILLION)
  • TABLE 238. EUROPEAN UNION MULTIPLE MYELOMA DRUG MARKET SIZE, BY GENDER, 2018-2032 (USD MILLION)
  • TABLE 239. EUROPEAN UNION MULTIPLE MYELOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 240. BRICS MULTIPLE MYELOMA DRUG MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 241. BRICS MULTIPLE MYELOMA DRUG MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 242. BRICS MULTIPLE MYELOMA DRUG MARKET SIZE, BY IMMUNOMODULATORY AGENTS, 2018-2032 (USD MILLION)
  • TABLE 243. BRICS MULTIPLE MYELOMA DRUG MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 244. BRICS MULTIPLE MYELOMA DRUG MARKET SIZE, BY PROTEASOME INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 245. BRICS MULTIPLE MYELOMA DRUG MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 246. BRICS MULTIPLE MYELOMA DRUG MARKET SIZE, BY TREATMENT REGIMEN, 2018-2032 (USD MILLION)
  • TABLE 247. BRICS MULTIPLE MYELOMA DRUG MARKET SIZE, BY COMBINATION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 248. BRICS MULTIPLE MYELOMA DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 249. BRICS MULTIPLE MYELOMA DRUG MARKET SIZE, BY PATIENT AGE, 2018-2032 (USD MILLION)
  • TABLE 250. BRICS MULTIPLE MYELOMA DRUG MARKET SIZE, BY GENDER, 2018-2032 (USD MILLION)
  • TABLE 251. BRICS MULTIPLE MYELOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 252. G7 MULTIPLE MYELOMA DRUG MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 253. G7 MULTIPLE MYELOMA DRUG MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 254. G7 MULTIPLE MYELOMA DRUG MARKET SIZE, BY IMMUNOMODULATORY AGENTS, 2018-2032 (USD MILLION)
  • TABLE 255. G7 MULTIPLE MYELOMA DRUG MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 256. G7 MULTIPLE MYELOMA DRUG MARKET SIZE, BY PROTEASOME INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 257. G7 MULTIPLE MYELOMA DRUG MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 258. G7 MULTIPLE MYELOMA DRUG MARKET SIZE, BY TREATMENT REGIMEN, 2018-2032 (USD MILLION)
  • TABLE 259. G7 MULTIPLE MYELOMA DRUG MARKET SIZE, BY COMBINATION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 260. G7 MULTIPLE MYELOMA DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 261. G7 MULTIPLE MYELOMA DRUG MARKET SIZE, BY PATIENT AGE, 2018-2032 (USD MILLION)
  • TABLE 262. G7 MULTIPLE MYELOMA DRUG MARKET SIZE, BY GENDER, 2018-2032 (USD MILLION)
  • TABLE 263. G7 MULTIPLE MYELOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 264. NATO MULTIPLE MYELOMA DRUG MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 265. NATO MULTIPLE MYELOMA DRUG MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 266. NATO MULTIPLE MYELOMA DRUG MARKET SIZE, BY IMMUNOMODULATORY AGENTS, 2018-2032 (USD MILLION)
  • TABLE 267. NATO MULTIPLE MYELOMA DRUG MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 268. NATO MULTIPLE MYELOMA DRUG MARKET SIZE, BY PROTEASOME INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 269. NATO MULTIPLE MYELOMA DRUG MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 270. NATO MULTIPLE MYELOMA DRUG MARKET SIZE, BY TREATMENT REGIMEN, 2018-2032 (USD MILLION)
  • TABLE 271. NATO MULTIPLE MYELOMA DRUG MARKET SIZE, BY COMBINATION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 272. NATO MULTIPLE MYELOMA DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 273. NATO MULTIPLE MYELOMA DRUG MARKET SIZE, BY PATIENT AGE, 2018-2032 (USD MILLION)
  • TABLE 274. NATO MULTIPLE MYELOMA DRUG MARKET SIZE, BY GENDER, 2018-2032 (USD MILLION)
  • TABLE 275. NATO MULTIPLE MYELOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 276. GLOBAL MULTIPLE MYELOMA DRUG MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 277. UNITED STATES MULTIPLE MYELOMA DRUG MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 278. UNITED STATES MULTIPLE MYELOMA DRUG MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 279. UNITED STATES MULTIPLE MYELOMA DRUG MARKET SIZE, BY IMMUNOMODULATORY AGENTS, 2018-2032 (USD MILLION)
  • TABLE 280. UNITED STATES MULTIPLE MYELOMA DRUG MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 281. UNITED STATES MULTIPLE MYELOMA DRUG MARKET SIZE, BY PROTEASOME INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 282. UNITED STATES MULTIPLE MYELOMA DRUG MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 283. UNITED STATES MULTIPLE MYELOMA DRUG MARKET SIZE, BY TREATMENT REGIMEN, 2018-2032 (USD MILLION)
  • TABLE 284. UNITED STATES MULTIPLE MYELOMA DRUG MARKET SIZE, BY COMBINATION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 285. UNITED STATES MULTIPLE MYELOMA DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 286. UNITED STATES MULTIPLE MYELOMA DRUG MARKET SIZE, BY PATIENT AGE, 2018-2032 (USD MILLION)
  • TABLE 287. UNITED STATES MULTIPLE MYELOMA DRUG MARKET SIZE, BY GENDER, 2018-2032 (USD MILLION)
  • TABLE 288. UNITED STATES MULTIPLE MYELOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 289. CHINA MULTIPLE MYELOMA DRUG MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 290. CHINA MULTIPLE MYELOMA DRUG MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 291. CHINA MULTIPLE MYELOMA DRUG MARKET SIZE, BY IMMUNOMODULATORY AGENTS, 2018-2032 (USD MILLION)
  • TABLE 292. CHINA MULTIPLE MYELOMA DRUG MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2032 (USD MILLION)
  • TABLE 293. CHINA MULTIPLE MYELOMA DRUG MARKET SIZE, BY PROTEASOME INHIBITORS, 2018-2032 (USD MILLION)
  • TABLE 294. CHINA MULTIPLE MYELOMA DRUG MARKET SIZE, BY LINE OF THERAPY, 2018-2032 (USD MILLION)
  • TABLE 295. CHINA MULTIPLE MYELOMA DRUG MARKET SIZE, BY TREATMENT REGIMEN, 2018-2032 (USD MILLION)
  • TABLE 296. CHINA MULTIPLE MYELOMA DRUG MARKET SIZE, BY COMBINATION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 297. CHINA MULTIPLE MYELOMA DRUG MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 298. CHINA MULTIPLE MYELOMA DRUG MARKET SIZE, BY PATIENT AGE, 2018-2032 (USD MILLION)
  • TABLE 299. CHINA MULTIPLE MYELOMA DRUG MARKET SIZE, BY GENDER, 2018-2032 (USD MILLION)
  • TABLE 300. CHINA MULTIPLE MYELOMA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)